Literature DB >> 6466177

Effect of insulin infusion pump use on diabetic retinopathy.

T M Kelly, G E Sanborn, P J Haug, C Q Edwards.   

Abstract

Ten patients with insulin-dependent diabetes mellitus (IDDM) had fundus photographs and fluorescein angiograms obtained before and after a control period characterized by conventional insulin injections and a test period characterized by continuous subcutaneous insulin infusion (CSII). The mean glycosylated hemoglobin value at the end of the control period was 14.3% +/- 3.8% and decreased to 10.1% +/- 3.3% at the end of the test period. During the control period, none of the patients' eyes changed more than one grade in a modified Early Treatment Diabetic Retinopathy Study classification. All seven eyes without retinopathy at the start of the control period were still without retinopathy at its completion. One eye improved three grades during the test period, but four eyes, including two without retinopathy when CSII was initiated, progressed one grade. The data suggest that metabolic control that is improved but not normalized by CSII neither reverses retinopathy in IDDM nor prevents its development.

Entities:  

Mesh:

Year:  1984        PMID: 6466177     DOI: 10.1001/archopht.1984.01040030934017

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  3 in total

1.  Insulin Delivery Hardware: Pumps and Pens.

Authors:  Rayhan Lal; Lalantha Leelarathna
Journal:  Diabetes Technol Ther       Date:  2022-03       Impact factor: 7.337

2.  Effect of cyclospasmol on early diabetic retinopathy.

Authors:  M C Mota; E Leite; M A Ruas; H L Verjans; C B Blakemore; J G Cunha-Vaz
Journal:  Int Ophthalmol       Date:  1987-02       Impact factor: 2.031

3.  Continuous subcutaneous insulin infusion therapy is associated with reduced retinopathy progression compared with multiple daily injections of insulin.

Authors:  Laura J Reid; Fraser W Gibb; Helen Colhoun; Sarah H Wild; Mark W J Strachan; Karen Madill; Baljean Dhillon; Shareen Forbes
Journal:  Diabetologia       Date:  2021-05-08       Impact factor: 10.122

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.